OBJECTIVES: To determine the impact of time between initiating highly active antiretroviral therapy (HAART) and delivery-duration of antenatal HAART-on perinatal HIV infection. DESIGN: We conducted a retrospective cohort analysis of pregnant HIV-infected women in Lusaka, Zambia. Women in our cohort were receiving HAART and had an infant HIV polymerase chain reaction test between 3 and 12 weeks of life. METHODS: We examined factors associated with infant HIV infection and performed a locally weighted regression analysis to examine the effect of duration of antenatal HAART on perinatal HIV infection. RESULTS: : From January 2007 to March 2010, 1813 HIV-infected pregnant women met inclusion criteria. Mean gestational age at first antenatal visit was 21 weeks (SD ± 6), median CD4+ cell count was 231 cells per microliter (interquartile range: 164-329), and median duration of antenatal HAART was 13 weeks (interquartile range 8-19). Fifty-nine (3.3%) infants were HIV infected. Duration of antenatal HAART was the most important predictor of perinatal HIV transmission. Compared with women initiating HAART at least 13 weeks before delivery, women on HAART for ≤4 weeks had a 5.5-fold increased odds of HIV transmission (95% confidence interval: 2.6 to 11.7). Locally weighted regression analysis suggested limited additional prophylactic benefit beyond 13 weeks on antenatal HAART. CONCLUSIONS: Low rates of mother-to-child HIV transmission can be achieved within programmatic settings in Africa. Maximal effectiveness of prevention of mother-to-child transmission programs is achieved by initiating HAART at least 13 weeks before delivery.
OBJECTIVES: To determine the impact of time between initiating highly active antiretroviral therapy (HAART) and delivery-duration of antenatal HAART-on perinatal HIV infection. DESIGN: We conducted a retrospective cohort analysis of pregnant HIV-infectedwomen in Lusaka, Zambia. Women in our cohort were receiving HAART and had an infant HIV polymerase chain reaction test between 3 and 12 weeks of life. METHODS: We examined factors associated with infantHIV infection and performed a locally weighted regression analysis to examine the effect of duration of antenatal HAART on perinatal HIV infection. RESULTS: : From January 2007 to March 2010, 1813 HIV-infected pregnant women met inclusion criteria. Mean gestational age at first antenatal visit was 21 weeks (SD ± 6), median CD4+ cell count was 231 cells per microliter (interquartile range: 164-329), and median duration of antenatal HAART was 13 weeks (interquartile range 8-19). Fifty-nine (3.3%) infants were HIV infected. Duration of antenatal HAART was the most important predictor of perinatal HIV transmission. Compared with women initiating HAART at least 13 weeks before delivery, women on HAART for ≤4 weeks had a 5.5-fold increased odds of HIV transmission (95% confidence interval: 2.6 to 11.7). Locally weighted regression analysis suggested limited additional prophylactic benefit beyond 13 weeks on antenatal HAART. CONCLUSIONS: Low rates of mother-to-child HIV transmission can be achieved within programmatic settings in Africa. Maximal effectiveness of prevention of mother-to-child transmission programs is achieved by initiating HAART at least 13 weeks before delivery.
Authors: Benjamin H Chi; Namwinga Chintu; Alison Lee; Elizabeth M Stringer; Moses Sinkala; Jeffrey S A Stringer Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Victor Mwapasa; Stephen J Rogerson; Jesse J Kwiek; Paul E Wilson; Danny Milner; Malcolm E Molyneux; Deborah D Kamwendo; Eyob Tadesse; Ebbie Chaluluka; Steven R Meshnick Journal: AIDS Date: 2006-09-11 Impact factor: 4.177
Authors: Jeffrey S A Stringer; Isaac Zulu; Jens Levy; Elizabeth M Stringer; Albert Mwango; Benjamin H Chi; Vilepe Mtonga; Stewart Reid; Ronald A Cantrell; Marc Bulterys; Michael S Saag; Richard G Marlink; Alwyn Mwinga; Tedd V Ellerbrock; Moses Sinkala Journal: JAMA Date: 2006-08-16 Impact factor: 56.272
Authors: Taha E Taha; Donald R Hoover; Newton I Kumwenda; Susan A Fiscus; George Kafulafula; Chiwawa Nkhoma; Shu Chen; Estelle Piwowar; Robin L Broadhead; J Brooks Jackson; Paolo G Miotti Journal: J Infect Dis Date: 2007-05-24 Impact factor: 5.226
Authors: Michael G Hudgens; Taha E Taha; Saad B Omer; Denise J Jamieson; Hana Lee; Lynne M Mofenson; Charles Chasela; Athena P Kourtis; Newton Kumwenda; Andrea Ruff; Abubaker Bedri; J Brooks Jackson; Philippa Musoke; Robert C Bollinger; Nikhil Gupte; Michael C Thigpen; Allan Taylor; Charles van der Horst Journal: Clin Infect Dis Date: 2012-09-20 Impact factor: 9.079
Authors: Kate Clouse; Audrey Pettifor; Kate Shearer; Mhairi Maskew; Jean Bassett; Bruce Larson; Annelies Van Rie; Ian Sanne; Matthew P Fox Journal: Trop Med Int Health Date: 2013-02-03 Impact factor: 2.622
Authors: Amitabh B Suthar; David Hoos; Alba Beqiri; Karl Lorenz-Dehne; Craig McClure; Chris Duncombe Journal: Bull World Health Organ Date: 2012-11-28 Impact factor: 9.408